Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00855413
Other study ID # CID 0821
Secondary ID
Status Terminated
Phase Phase 4
First received March 2, 2009
Last updated September 12, 2017
Start date March 2009
Est. completion date November 2013

Study information

Verified date September 2017
Source University of North Carolina, Chapel Hill
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Purpose: This is a pilot study to evaluate HIV viremia and persistence in acutely HIV infected antiretroviral naïve patients treated with Darunavir/ritonavir and Etravirine

Participants: 20 participants, age 18 and older, HIV infected, antiretroviral naïve patients

Procedures (methods): ARV treatment with Darunavir/ritonavir and Etravirine,

Optional studies:

Genital secretion samples, Cerebrospinal fluid samples, Leukapheresis, Endoscopy/colonoscopy


Description:

Study Design

This is a multicenter, single arm, 48-week open-label pilot study of DRV/R & ETR in acute HIV infection. Study sites will be members of the Duke-UNC Acute HIV Infection Study Consortium. If baseline resistance is detected after treatment begins (e.g. evidence of pre-existing baseline resistance (genotypic or phenotypic) that may adversely affect the efficacy of the study regimen), the patient may elect to alter treatment as per best clinical practice. The new regimen will not be provided by the study, but will be obtained for the participant through available clinical resources.

After patients are identified with acute HIV infection, they will be offered the opportunity to participate in the study. Patients will also be offered the opportunity to co-enroll in CHAVI 001 and 012, studies that follow the virological and immunological response of patients with AHI, regardless of the initiation of ART. An overall consent form will be signed for study participation, and separate informed consents with signatures will be obtained for optional studies. Patients will be eligible for participation after signing the overall consent - agreeing to participate in studies of other compartment specimens is not required for enrollment. At the initial visit, patient eligibility will be confirmed with appropriate laboratory testing (see "STUDY POPULATION"). When eligibility is verified, entry laboratory studies will be obtained, and the participants will be started on DRV/r, and ETR. All participants will be followed at regular intervals thereafter as specified in the schedule of evaluations. Participants meeting criteria for virologic failure will be offered the opportunity to switch to the best available regimen as selected by their HIV provider.

Hypothesis

Combination therapy with DRV/R & ETR will suppress plasma viremia and improve immunologic function in antiretroviral (ART)-naïve, acutely HIV-infected (AHI) patients, and will limit replication in HIV-1 cellular compartments.


Recruitment information / eligibility

Status Terminated
Enrollment 15
Est. completion date November 2013
Est. primary completion date November 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Documentation of Acute HIV Infection as defined above.

2. Men and women age =18 years.

3. Participants will be ART naïve, defined as =14 days of antiretroviral treatment at any time prior to entry. The only exceptions are: Post-exposure prophylaxis (PEP) provided the patient was documented as HIV-1 negative at least 3-6 months after completion of the PEP treatment.

4. Screening HIV-1 RNA >1,000 copies/mL obtained within 30 days at study entry.

5. Lab values obtained within 30 days prior to study entry:

6. Absolute neutrophil count >500/mm3

7. Hemoglobin > 8.5 g/dL for men and > 8.0 g/dL for women

8. Platelet count >50,000/mm3

9. AST (SGOT) =2.5 x ULN

10. ALT (SGPT) =2.5 x ULN

11. Total bilirubin <2.5 x ULN

12. Calculated creatinine clearance (Cockcroft-Gault formula) > 30mL/min:

- CrCl = (140-age) x body weight (kg) (x 0.85 if female)

- Serum creatinine [mg/dL] x (72)

13. For women of reproductive potential, a negative serum or urine pregnancy test within 7 days prior to initiating antiretroviral study medications. Reproductive potential is defined as females who have reached menarche and have not been post-menopausal for at least 24 consecutive months, or have not undergone surgical sterilization (e.g., hysterectomy, bilateral oophorectomy, or salpingotomy). Acceptable documentation of surgical sterilization includes patient-reported history.

14. If participating in sexual activity that could lead to pregnancy, female study patients must use at least one form of contraception, which could consist only of a barrier method. All patients must continue to use contraception for 6 weeks after stopping the study medications. Acceptable methods of contraception include: condoms (male or female) with or without spermicidal agent, diaphragm or cervical cap with spermicide, or IUD. Female volunteers not of reproductive potential are not required to use contraception.

15. Ability and willingness of patient to give written informed consent.

Exclusion Criteria:

1. Women who are pregnant or breast-feeding.

2. Women with a positive pregnancy test on enrollment or prior to study drug administration.

3. Women of reproductive potential who are unwilling or unable to use acceptable methods to avoid pregnancy for the entire study period

4. Use of immunomodulators (e.g., interleukins, interferons, cyclosporine), HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy within 30 days prior to study entry.

- Prednisone at a daily dose of 10 mg or less (physiologic replacement dose) is permitted.

5. Known allergy/sensitivity to study drugs or their formulations.

6. Difficulty swallowing capsules/tablets.

7. Inability to communicate effectively with study personnel.

8. Incarceration; prisoner recruitment and participation are not permitted.

9. Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements or confound the analysis of study endpoints.

10. Any active psychiatric illness including schizophrenia, severe depression, or severe bipolar affective disorder that, in the opinion of the investigator, could confound the analysis of the neurological examination or neuropsychological test results.

11. Active brain infection (except for HIV-1), brain neoplasm, space-occupying brain lesion requiring acute or chronic therapy. Participants with any fungal meningitis, parasitic infection, or CNS lymphoma are excluded from participation.

12. Serious illness requiring systemic treatment and/or hospitalization until patient either completes therapy or is clinically stable on therapy, in the opinion of the site investigator, for at least 7 days prior to study entry. NOTE: Oral candidiasis, vaginal candidiasis, mucocutaneous herpes simplex, and other minor illnesses (as judged by the site investigator) have no restriction.

13. Known cardiac conduction disease.

14. Prior treatment with any other experimental drug for any indication (within 30 days of initiating study treatment).

15. Unable to discontinue any current medications that are excluded during study treatment.

16. A life expectancy less than twelve months.

17. Acute Viral Hepatitis, including, but not limited to, Hepatitis A, B, or C

18. Chronic Hepatitis B Infection documented by a detectable serum Hepatitis B surface antigen (HBsAg) or plasma HBV DNA

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Darunavir
800 mg orally once daily
Ritonavir
100 mg orally once daily
Etravirine
200 mg orally twice daily, although patients may choose to take ETR 400 mg QD to have a simpler all QD regimen

Locations

Country Name City State
United States The University of North Carolina - Chapel Hill Chapel Hill North Carolina
United States Duke University Durham North Carolina

Sponsors (2)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill Janssen Pharmaceuticals

Country where clinical trial is conducted

United States, 

References & Publications (2)

C Gay, A Johnson, S McCoy, J Kuruc, K McGee, L McNeil, M Kerkau, J Sebastian, C Pilcher, D Margolis, P Leone, S Fiscus, G Ferrari, C Hicks, J Eron, The Duke-UNC Acute HIV Infection Consortium. "Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection." XVII International AIDS Conference, 2008 Abstract no. THPE0082.

C Gay, O Dibben, A Stacey, N Gasper-Smith, M Liu, N Goonetilleke, G Ferrari, J Eron, C Hicks, A McMichael, B Haynes, P Borrow, M Cohen, the Duke-UNC CHAVI 001 Clinical Working Group. "Effect(s) of antiretroviral treatment on acute HIV infection." XVII International AIDS Conference, 2008 Abstract no. THPE0086.

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Virologic Response Virologic response defined as plasma HIV RNA measurement <200 copies/mL at week 24 24 weeks
Secondary Number of Participants With Virologic Response Virologic response to study treatment defined as plasma HIV RNA measurement <50 copies/mL at week 48 48 weeks from enrollment
Secondary Median Change in CD4 Cell Count From Week 0 to Week 24. week 0, week 24
Secondary Median Change in CD4 Cell Count From Week 0 to Week 48. 48 weeks from enrollment
Secondary HIV RNA Levels Immediately Prior to Initiating Study Treatment. HIV RNA level at enrollment
Secondary Median Time to HIV RNA Suppression to <200 Copies/mL From enrollment to the date of HIV RNA suppression, assessed up to Week 48
Secondary HIV RNA Detection in Semen Total cumulative levels of HIV RNA detected in the semen of participants from enrollment through week 48. From enrollment through 48 weeks
Secondary Number of Participants Who Stopped Study Treatment Due to Adverse Event or Intolerance Enrollment to Week 48
Secondary Adverse Events Possibly or Definitely Related to Study Treatment Through Week 48 Total number of adverse events observed that were possibly or definitely related to study treatment through week 48 Enrollment to week 48
Secondary Maximum Etravirine Exposure in Cerebrospinal Fluid Among Participants Who Consented to an Optional Lumbar Puncture Week 4 and week 48
Secondary Minimum Etravirine Exposure in Cerebrospinal Fluid Among Participants Who Consented to an Optional Lumbar Puncture Week 4 and week 48
Secondary Maximum Darunavir Exposure in Cerebrospinal Fluid Among Participants Who Consented to an Optional Lumbar Puncture Week 4 and week 48
Secondary Minimum Darunavir Exposure in Cerebrospinal Fluid Among Participants Who Consented to an Optional Lumbar Puncture Week 4 and week 48
Secondary Maximum Ritonavir Exposure in Cerebrospinal Fluid Among Participants Who Consented to an Optional Lumbar Puncture Week 4 and Week 48
Secondary Minimum Ritonavir Exposure Range in Cerebrospinal Fluid Among Participants Who Consented to an Optional Lumbar Puncture Week 4 and week 48
Secondary Maximum Etravirine Exposure in Semen Among Participants Who Consented to an Optional Collection of Semen Weeks 0-4 and weeks 12, 48
Secondary Minimum Etravirine Exposure in Semen Among Participants Who Consented to an Optional Collection of Semen Weeks 0-4 and weeks 12, 48
Secondary Maximum Darunavir Exposure in Semen Among Participants Who Consented to an Optional Collection of Semen Weeks 0-4 and weeks 12, 48
Secondary Minimum Darunavir Exposure Range in Semen Among Participants Who Consented to an Optional Collection of Semen Weeks 0-4 and weeks 12, 48
Secondary Maximum Ritonavir Exposure in Semen Among Participants Who Consented to an Optional Collection of Semen Weeks 0-4 and Weeks 12, 48
Secondary Minimum Ritonavir Exposure in Semen Among Participants Who Consented to an Optional Collection of Semen Weeks 0-4 and Weeks 12, 48
Secondary Maximum Etravirine Exposure in Ileal Tissue Among Participants Who Consented to an Optional Gut Biopsy Procedure between Week 4-12 and between Weeks 36-48
Secondary Minimum Etravirine Exposure Range in Ileal Tissue Among Participants Who Consented to an Optional Gut Biopsy Procedure between Week 4-12 and between Weeks 36-48
Secondary Maximum Darunavir Exposure Range in Ileal Tissue Among Participants Who Consented to an Optional Gut Biopsy Procedure between Week 4-12 and between Weeks 36-48
Secondary Minimum Darunavir Exposure Range in Ileal Tissue Among Participants Who Consented to an Optional Gut Biopsy Procedure between week 4-12 and between weeks 36-48
Secondary Maximum Ritonavir Exposure Range in Ileal Tissue Among Participants Who Consented to an Optional Gut Biopsy Procedure between week 4-12 and between Weeks 36-48
Secondary Minimum Ritonavir Exposure Range in Ileal Tissue Among Participants Who Consented to an Optional Gut Biopsy Procedure between week 4-12 and between weeks 36-48
Secondary Number of Participants With HIV RNA Measurement Above the Limits of Detection in Cerebrospinal Fluid Week 4 and Week 48
Secondary Number of Participants With Neurocognitive Impairment at Baseline Week 2 or 4
Secondary Number of Participants With Neurocognitive Impairment at Week 24 Week 24
Secondary Number of Participants With Neurocognitive Impairment at Week 48 Week 48
Secondary Overall Neurocognitive Impairment Score at Week 2 or 4 Neuropsychological performance was assessed at Week 2 or 4, Week 24 and Week 48 in the following measures: Premorbid/language (Wide Range Achievement Test 4 -Reading Subtest), Learning (HVLT-R, Hopkins Verbal Learning Test-Revised), Memory (HVLT-R), Speed of Processing (Trailmaking A (Army Individual Test Battery, 1944), 1974, Stroop color, Attention (WAIS-III Symbol Search; Stroop word, Fine motor, Executive (Trailmaking B, Stroop interference, Letter, Category Fluency. An overall summary score was created by averaging all tests. Participants also completed the self-reported functional status Patient's Assessment of Own Functioning Inventory (PAOFI) and the Activities of Daily Living Scale (ADLS). Best available demographically corrected normative data were utilized to create z scores. A negative z score denotes below-average performance relative to a US normative comparison population. A higher z score is a better outcome. Week 2 or 4
Secondary Overall Neurocognitive Impairment at Week 24 Neuropsychological performance was assessed at week 2 or 4, week 24 and week 48 in the following measures: Premorbid/language (Wide Range Achievement Test 4 -Reading Subtest), Learning (Hopkins Verbal Learning Test - Revised), Memory (HVLT-R), Speed of Processing (Trailmaking A (Army Individual Test Battery, 1944), 1974, Stroop color, Attention (WAIS-III Symbol Search; Stroop word, Fine motor, Executive (Trailmaking B, Stroop interference, Letter, Category Fluency. An overall summary score of neurocognitive functioning was created by averaging all tests. Participants also completed Patient's Assessment of Own Functioning Inventory (PAOFI) and the Activities of Daily Living Scale (ADLS). Best available demographically corrected normative data were utilized to create z scores. A negative z score denotes below-average performance relative to a US normative comparison population. A higher z score is a better outcome. Week 24
Secondary Overall Neurocognitive Impairment at Week 48 Neuropsychological performance was assessed at baseline (week 2 or 4), week 24 and week 48 in the following domain (measures): Premorbid/language (Wide Range Achievement Test (WRAT) 4 - Reading Subtest), Learning (HVLT-R, Hopkins Verbal Learning Test - Revised), Memory (HVLT-R), Speed of Processing (Trailmaking A (Army Individual Test Battery, 1944), 1974, Stroop color, Attention (WAIS-III Symbol Search; Stroop word, Fine motor, Executive (Trailmaking B, Stroop interference, Letter, Category Fluency. An overall summary score of neurocognitive functioning was created by averaging all tests. Participants also completed the self-reported functional status Patient's Assessment of Own Functioning Inventory (PAOFI) and the Activities of Daily Living Scale (ADLS). Best available demographically corrected normative data were utilized to create z scores. A negative z score denotes below-average performance relative to a US normative comparison population. A higher z score is a better outcome. Week 48
Secondary Change in Overall Neurocognitive Impairment From Baseline to Week 24 or 48 Change in overall z score from baseline to week 24 or 48. A negative z score denotes below-average performance relative to a US normative comparison population. A higher z score is a better outcome. Baseline to Week 24 or 48
Secondary Correlation of HIV RNA Levels in CSF and Drug Levels With Neurocognitive Functioning From enrollment through Week 48
Secondary Correlation of Time to HIV RNA Levels <200 Copies/mL With Improvement in Neurocognitive Functioning From Baseline to Week 24 and 48 Baseline to Week 24 and 48
Secondary HIV RNA Detection in Ileal Biopsy Specimens Average HIV RNA detected in the ileal biopsy specimens per participant over weeks 4 and 48. Weeks 4 and 48
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2